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Dr Steven DeMeester (Los Angeles, Calif). I would like to congrat-
ulate Dr Weyant and his colleagues both for an excellent presenta-
tion and a very clearly written manuscript.
In this study the authors evaluated the role of sPLA2 in a mouse
model of surgically induced gastroduodenoesophageal reflux. By
using an inbred mouse strain deficient in the gene for phospholipase
A2, they were able to ascertain the role of this enzyme in early
esophageal mucosal changes associated with reflux. Compared
with normal mice, the knockout mice showed significantly less in-
crease in epithelial thickness and in Ki67 activity, with levels in
the knockout mice equivalent to those in control animals. They con-
clude that phospholipase A2 is involved in the early squamous mu-
cosal changes associated with gastroduodenoesophageal reflux.
The authors are to be congratulated for several things. First, they
successfully developed this mouse model of surgically induced1226 The Journal of Thoracic and Cardiovascular Surgery c Jureflux, which has been a hurdle for many investigators in the past.
Second, they demonstrate that the phospholipase A2 protein can
be found in esophageal tissue in the mouse. Third, they designed
an elegant first experiment by using a mouse knockout model for
this gene to demonstrate the role of phospholipase A2 in early squa-
mous esophageal mucosal injury associated with reflux. I have 3
questions for you.
First, changes in esophageal mucosal thickness or the old (Ish-
mael Bagay) criteria for reflux are known to be quite nonspecific.
Recent work by Ray Orlando and colleagues using transmission
electron microscopy to look at dilated intracellular channels sug-
gests that this might represent a very sensitive and specific way to
assess early mucosal changes associated with reflux. Have you con-
sidered using transmission electron microscopy to evaluate in the
mouse the presence or absence of these dilated intracellular chan-
nels?
DrWeyant. I am aware of the technique, but at our institution, it
is difficult to achieve the use of that specific technique, although it is
something that we are certainly interested in looking at in the future.
Dr Demeester. Second, the really significant (ie, premalignant)
changes that occur with reflux involve the transformation of the
squamous esophageal mucosa to columnar cardiac mucosa and
then subsequently to intestinal metaplasia. Do you anticipate that
with a longer duration of reflux in this mouse model that these his-
tologic changes will occur? In other words, can you replicate in the
mouse model what has been shown to occur in the rat model of gas-
troduodenoesophageal reflux?
DrWeyant. I believe we can. I am certainly very optimistic that
we can. Even after 4 weeks in some of these mice, we are actually
able to see changes that appear to be the early morphologic changes
consistent with Barrett’s esophagus. I did not have the time to show
the slides here, but our next phase of these studies is going to be to
take these mice and reflux them for several weeks, up to 40 weeks,
and harvest the mice at several different time periods so that we have
the whole spectrum of carcinogenesis of gastroesophageal junction
adenocarcinoma; that will then allow us to study all of these molec-
ular markers at these different time points in this model, as well as
using the similar model in other genetic backgrounds, such as
a P53 knockout mouse and others that are available, where we can
apply this model now that we are proficient in it.
Dr Demeester. Lastly, although there is no doubt that a link be-
tween inflammation and cancer exists, the nature of that relationship
is very complex. Rebecca Fitzgerald, in addition to work from our
own laboratory, has shown that there is an inflammatory gradient
within Barrett’s esophagus with maximal expression of inflamma-
tory genes proximally in a Barrett’s esophagus segment, yet many
of the cancers occur distally in areas with much lower levels of in-
flammatory gene expression. In light of this, can you give us your
thoughts on the role of phospholipase A2 and what its role might
be in carcinogenesis within Barrett’s esophagus? Do you think it
is an early mediator of progression in Barrett’s esophagus or merely
a marker for injury?
Congratulations again and thank you for the opportunity to dis-
cuss this paper.
Dr Weyant. Thank you very much for your comments, Dr De-
Meester.
Part of our next phase of these studies also goes along with what
our next main hypothesis is regarding the function of sPLA2 in thatne 2008
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hyperplasia and thickening of the mucosa, but what that really points
to for me is that sPLA2 is somehow a growth regulator in esophageal
mucosa. Some of the articles I have listed on one of the previous
slides are some of the less well-known literature regarding sPLA2,
and not one of them has sort of hit on the main point that it interacts
with EGF receptor and its ligand, whichwe know is already a growth
factor in esophageal mucosa, as well as other growth factors. Again,
these are reported in other tissues using different models, but I think
our next step is to apply those hypotheses to this model to see really
how sPLA2 acts as a growth factor in esophageal mucosa, and I think
we will.
Doctor. I have a quick follow-up question for you, which speaks
to my inherent suspicion of knockout mice. Can you comment more
on these collateral secretory phenotypic changes associated with the
black-6 mouse? In other words, I appreciate that your inhibitor stud-
ies validate that phospholipase A2 is at least a necessary cofactor inThe Journal of Thorthis preparation, but are there any other changes that result from this
particular genetic variation as relates to acid or bile salt excretion?
DrWeyant. As far as other experience goes, no. That is a contin-
ual concern of ours, and data that I did not present here that we have
also recently accumulated in the laboratory—there is actually
a mouse available with a black-6 background that has the sPLA2
gene reintroduced into it. Whenwe do this samemodel here compar-
ing a black-6 wild-type mouse and a black-6 mouse that has the
sPLA2 gene reintroduced, we get the same findings of the hyperpla-
sia and thickening of mucosa. Between the inhibitor studies and
what we call the ‘‘knock-in’’ studies, that is as confident as I can
be that we are actually seeing a real change here. The reason we
went to these lengths of using the inhibitor study and the knock-in
mouse was because of those concerns that we shared also.
Doctor. I agree. Excellent job. Elegant work, and everybody on
the project should be commended on technically pulling this off.
That is a real feat of technical expertise. Congratulations.acic and Cardiovascular Surgery c Volume 135, Number 6 1227
